Advertisement

Topics

LY317615 in Treating Patients With Recurrent Gliomas

2014-08-27 03:55:34 | BioPortfolio

Summary

RATIONALE: LY317615 may stop the growth of gliomas by stopping blood flow to the tumor.

PURPOSE: This phase II trial is studying how well LY317615 works in treating patients with recurrent glioma.

Description

OBJECTIVES:

- Determine the anti-tumor activity of LY317615 in patients with recurrent high-grade gliomas.

- Determine the toxic effects of this drug in these patients.

OUTLINE: Patients are stratified according to tumor type (anaplastic astrocytoma vs glioblastoma multiforme) and concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs) (no vs yes).

Patients receive oral LY317615 once daily for 6 weeks. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity. Patients may receive additional courses beyond the 9 courses of therapy at the investigator's discretion.

Patients are followed within 2 weeks after the completion of therapy.

PROJECTED ACCRUAL: A maximum of 150 patients will be accrued for this study within 1 year.

Study Design

Masking: Open Label, Primary Purpose: Treatment

Conditions

Brain and Central Nervous System Tumors

Intervention

enzastaurin hydrochloride

Location

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda
Maryland
United States
20892-1182

Status

Completed

Source

National Cancer Institute (NCI)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:55:34-0400

Clinical Trials [3909 Associated Clinical Trials listed on BioPortfolio]

Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors

RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is st...

Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas

RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such a...

Enzastaurin and Bevacizumab in Treating Patients With Recurrent Malignant Gliomas

RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in diff...

Natural History Study of Patients With Central Nervous System Tumors Being Evaluated at the National Institutes of Health

RATIONALE: Gathering information about patients with central nervous system tumors over time may help doctors learn more about the disease and find better methods of treatment and on-going...

Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children

RATIONALE: Genetic studies may help in understanding the genetic processes involved in the development of some types of cancer. PURPOSE: Genetic study to learn more about genes involved i...

PubMed Articles [20591 Associated PubMed Articles listed on BioPortfolio]

Role of endothelial-to-mesenchymal transition in the pathogenesis of central nervous system hemangioblastomas.

Hemangioblastomas (HBs) are benign vascular tumors of the central nervous system and histologically contain abundant microvessels. Therefore, they clinically exhibit vascular malformation-like charact...

Primary Tumors of the Central Nervous System. Clinical Experience at a Third Level Center.

Central nervous system (CNS) tumors are a group of neoplasms that originate from various cells in the CNS. The increasing incidence and prevalence of this type of tumor in developing countries are str...

The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone.

Social Adjustment in Adolescent Survivors of Pediatric Central Nervous System Tumors: A Report From the Childhood Cancer Survivor Study.

The purpose of this study was to examine the prevalence and predictors of social difficulties in adolescent survivors of central nervous system (CNS) tumors.

Serum VEGF-A concentrations in patients with central nervous system (CNS) tumors.

Angiogenesis plays an essential role in tumors development. In case of central nervous system tumors, the most important role in this process plays VEGF-A. The purpose of this study was to determine t...

Medical and Biotech [MESH] Definitions

Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.

A group of malignant tumors of the nervous system that feature primitive cells with elements of neuronal and/or glial differentiation. Use of this term is limited by some authors to central nervous system tumors and others include neoplasms of similar origin which arise extracranially (i.e., NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL). This term is also occasionally used as a synonym for MEDULLOBLASTOMA. In general, these tumors arise in the first decade of life and tend to be highly malignant. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2059)

Diseases of the parasympathetic or sympathetic divisions of the AUTONOMIC NERVOUS SYSTEM; which has components located in the CENTRAL NERVOUS SYSTEM and PERIPHERAL NERVOUS SYSTEM. Autonomic dysfunction may be associated with HYPOTHALAMIC DISEASES; BRAIN STEM disorders; SPINAL CORD DISEASES; and PERIPHERAL NERVOUS SYSTEM DISEASES. Manifestations include impairments of vegetative functions including the maintenance of BLOOD PRESSURE; HEART RATE; pupil function; SWEATING; REPRODUCTIVE AND URINARY PHYSIOLOGY; and DIGESTION.

The main information-processing organs of the nervous system, consisting of the brain, spinal cord, and meninges.

A vascular anomaly characterized by a radial or wedge-shaped arrangement of dilated VEINS draining into a larger vein in the brain, spinal cord, or the meninges. Veins in a venous angioma are surrounded by normal nervous tissue, unlike a CENTRAL NERVOUS SYSTEM CAVERNOUS HEMANGIOMA that lacks intervening nervous tissue. Drainage of venous angioma is fully integrated with the body's venous system, therefore, in most cases there is no clinical signs and rare bleeding.

More From BioPortfolio on "LY317615 in Treating Patients With Recurrent Gliomas"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...


Searches Linking to this Trial